In a recent study focusing on familial Dysautonomia disease (FD), which is characterized by an autosomal recessive congenital neuropathy and impaired level of IκB kinase complex-associated protein (IKAP), a treatment protocol of a combination of kinetin with phosphatidyl serine (PS) or pridopidine increased the IKBKAP gene level with no side effects in comparison to PS or pridopidine alone [137]. This evidence concerns the gene ELP1 and Fabry disease.